Biosamples from the Framingham Heart Study will be used to Discover New Blood Tests for Heart Disease
WALTHAM, Mass., March 12 /PRNewswire/ -- BG Medicine, a biotechnology company focused on the discovery and development of novel diagnostic biomarkers, today announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health and
Under the agreement, the three parties will jointly conduct a series of biomarker discovery studies for heart disease and early detection of metabolic syndrome -- a combination of certain risk factors, including abdominal obesity, hypertension, and insulin resistance -- which are believed to increase the risk of developing cardiovascular disease and diabetes.
BG Medicine's highly advanced technology, which can detect and validate subtle biological changes at the molecular level, will analyze biosamples obtained during years of collection by Framingham Heart Study researchers. The Framingham Heart Study is funded by NHLBI and conducted in collaboration with BU's School of Medicine and School of Public Health.
The collaborative research aims to identify those at high risk of heart attack and stroke, two of the world's leading killers.
The research study -- Systems Approach to Biomarker Research in Cardiovascular Disease (SABRe CVD) -- may also aid pharmaceutical companies in developing novel medicines to prevent or treat these conditions.
The collaboration is the first time in the Framingham Heart Study's 60-year history that it is partnering with a commercial company in a CRADA research project.
"This research partnership could ultimately lead to simple blood tests for heart disease that could help us identify high-risk individuals earlier so they can take action sooner to pr
|SOURCE BG Medicine|
Copyright©2009 PR Newswire.
All rights reserved